Abstract library

1833 results for "Somatostatin receptor tumor volume".
#26 Molecular imaging of gastroenteropancreatic neuroendocrine tumours with Ga-68 DOTANOC PET/CT and correlation with an immunhistochemical quantification of somatostatin receptors using novel monoclonal and polyclonal antibodies
Introduction: Receptor PET/CT with somatostatin analogues marked with Gallium-68 (SMS-R-PET/CT) is currently the golden standard in diagnosing gastroenteropancreatic neuroendocrine tumors (GEP-NET), which are known for an overexpression of somatostatin receptors (SSTRs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer
#120 Somatostatin receptors 1-5 expression in a large series of well-differentiated neuroendocrine tumors
Introduction: For their antisecretive and antiproliferative effect somatostatin analogs (SA) have been used in the treatment of neuroendocrine tumors (NETs), based on the expression of somatostatin receptors (sstRs). The potential availability of new SA for the treatment of patients with NETs suggests a better characterization of sstRs.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Paola Loli
#183 Immunhistochemical Expression of Somatostatin Receptors in Gastroenteropancreatic Neuroendocrine Tumors Using IRS- and Her2-scoring Scheme
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are known for an overexpression of somatostatin receptors (SSTR). This finding has already gained importance in diagnostics and therapy of NET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Luisa Peter
Authors: Peter L, Kaemmerer D, Lupp A, Saenger J, ...
#195 UMB-4 as New Monoclonal Somatostatin Receptor Antibody: Correlation of Immunostaining with Molecular Imaging using Somatostatin Receptor PET/CT
Introduction: Somatostatin receptors (SSTR) are known for an overexpression in neuroendocrine tumors (NET).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
Authors: Kaemmerer D, Peter L, Lupp A, Schulz S, ...
#245 Expression of Somatostatin Receptors and Dopamine 2 Receptor in Lung Carcinoids as a Possible Biotherapy Target
Introduction: Expression of somatostatin receptors (SSTRs) and dopamine 2 receptor (D2R) in neuroendocrine tumors is of clinical importance, as somatostatin analogues and dopamine agonists are used in biotherapy.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Apostolos V. Tsolakis
#301 Medical and Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues (SSA) in Well- and Moderately Differentiated Neuroendocrine Tumors
Introduction: PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumors and this therapy seems more effective in the biochemical and volume control of disease than SSA alone.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#302 Monoclonal Antibodies Against the Human Somatostatin Receptor Subtypes 1-5: Characterization and Immunohistochemical Application in Gastrointestinal Neuroendocrine Tumors
Introduction: A lack of well-characterized somatostatin receptor (sstr)-specific antibodies has hampered development of routine sstr expression profiles that may be useful in the treatment of NET patients (pts).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Chiara Lambertini
#657 Correlation of Monoclonal and Polyclonal Somatostatin Receptor (SSTR) 5 Antibodies in Pancreatic Neuroendocrine Tumors
Introduction: For a few years now, highly specific monoclonal antibodies have been available to characterize neuroendocrine tumors for somatostatin-receptor (SSTR) expression.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr. Daniel Kaemmerer
Authors: Kaemmerer D, Lupp A, Peter L, Fischer E, ...
#689 Immunohistochemical Expression of Somatostatin Receptors 1, 2, 3, and 5 Types (SSR) in Functioning and Non-Functioning Gastroenteropancreatic Neuroendocrine Tumors
Introduction: SSRs are therapeutic targets for the somatostatin analogues in treatment of gasrtroenteropancreatic neuroendocrine tumors (GEP-NET).
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: MD Larisa Gurevich
#1048 The Additional Value of Somatostatin Receptor Scintigraphy During Preoperative Staging in Patients with Non-Functioning Pancreatic Neuroendocrine Tumors.
Introduction: During diagnostic workup for non-functioning pancreatic neuroendocrine tumors (NF-pNET) both computed tomography scan (CT-scan) and somatostatin receptor scintigraphy (SRS) are made.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Anneke Jilesen